Clinical & Medical Biochemistry

Internal Medicine A, Assaf Harofe Medical Center, Beer Yaakov, Israel

Biography

Shlomit Koren worked in a Internal Medicine A, Assaf Harofe Medical Center, Beer Yaakov, Israel  Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Shlomit Koren International experience includes various programs, contributions and participation in different countries for diverse fields of study.

Publications

• Research Article   
  Any Polymorphisms of CYP2C9 Affects the Biochemical Profile of Diabetic Patients Receiving Glibenclamide
  Author(s): Shlomit Koren, Ronit Koren, Adina Bar-Chaim, Patricia Benveniste-Levkovitz, Ahuva Golik and Amit Tirosh*
  
  Introduction: Glibenclamide, a hypoglycemic agent, is a member of the sulfonylurea family. It is metabolized by the hepatic P450 CYP2C9. Despite thorough pharmacokinetic characterization of glibenclamide, the evidence for a pharmacogenetic influence on the pharmacodynamics of this medication is scarce. The current study aims to evaluate a possible association between different CYP2C9 alleles and the pharmacodynamic effect of glibenclamide, including hypoglycemic events and required daily glibenclamide dosage. Methods: The patients included were aged ? 18 years, diagnosed with type II diabetes mellitus, and treated with metformin and glibenclamide for at least 3 months. Exclusion criteria were treatment with other hypoglycemic agents or with medications that affect CYP2C9 function. Patients underwent a medical interview, including detailed anti-glycemic treatment dosage and duration. B.. View more»
  

  DOI: 10.35248/2471-2663.1000102

  Abstract PDF